1-8 of 8
Ajay K. Gopal
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors

Johnnie J. Orozco, Phuong T. Vo, Ted A. Gooley, Robyn L. Haaf, Sally J. Lundberg, Donald K. Hamlin, D. Scott Wilbur, Manuela C. Matesan, Darrell R. Fisher, Ajay K. Gopal, Damian J. Green, John M. Pagel, Brenda M. Sandmaier
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (2): 274–282.
https://doi.org/10.1158/1078-0432.CCR-23-1200
Published: 17 January 2024
View article titled, Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors
Open the PDF for Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors in another window
Includes: Supplementary data
Journal Articles

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas

Ajay K. Gopal, Ronald Levy, Roch Houot, Sandip P. Patel, Leslie Popplewell, Caron Jacobson, Xinmeng J. Mu, Shibing Deng, Keith A. Ching, Ying Chen, Craig B. Davis, Bo Huang, Kolette D. Fly, Aron Thall, Adrian Woolfson, Nancy L. Bartlett
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2524–2534.
https://doi.org/10.1158/1078-0432.CCR-19-2973
Published: 01 June 2020
View article titled, First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20<sup>+</sup> Non-Hodgkin Lymphomas
Open the PDF for First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20<sup>+</sup> Non-Hodgkin Lymphomas in another window
Includes: Supplementary data
Journal Articles

Phase I Study of a CD45-Targeted Antibody–Radionuclide Conjugate for High-Risk Lymphoma

Ryan D. Cassaday, Oliver W. Press, John M. Pagel, Joseph G. Rajendran, Ted A. Gooley, Darrell R. Fisher, Leona A. Holmberg, Robert S. Miyaoka, Brenda M. Sandmaier, Damian J. Green, Ajay K. Gopal
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (23): 6932–6938.
https://doi.org/10.1158/1078-0432.CCR-19-1567
Published: 02 December 2019
View article titled, Phase I Study of a CD45-Targeted Antibody–Radionuclide Conjugate for High-Risk Lymphoma
Open the PDF for Phase I Study of a CD45-Targeted Antibody–Radionuclide Conjugate for High-Risk Lymphoma in another window
Includes: Supplementary data
Journal Articles

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

Radhakrishnan Ramchandren, Ranjana H. Advani, Stephen M. Ansell, Nancy L. Bartlett, Robert Chen, Joseph M. Connors, Tatyana Feldman, Andres Forero-Torres, Jonathan W. Friedberg, Ajay K. Gopal, Leo I. Gordon, John Kuruvilla, Kerry J. Savage, Anas Younes, Gerald Engley, Thomas J. Manley, Keenan Fenton, David J. Straus
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (6): 1718–1726.
https://doi.org/10.1158/1078-0432.CCR-18-2435
Published: 15 March 2019
View article titled, Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma
Open the PDF for Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

Neil H. Segal, Aiwu R. He, Toshihiko Doi, Ronald Levy, Shailender Bhatia, Michael J. Pishvaian, Rossano Cesari, Ying Chen, Craig B. Davis, Bo Huang, Aron D. Thall, Ajay K. Gopal
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (8): 1816–1823.
https://doi.org/10.1158/1078-0432.CCR-17-1922
Published: 12 April 2018
View article titled, Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
Open the PDF for Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab

Oliver W. Press, Joseph M. Unger, Lisa M. Rimsza, Jonathan W. Friedberg, Michael LeBlanc, Myron S. Czuczman, Mark Kaminski, Rita M. Braziel, Catherine Spier, Ajay K. Gopal, David G. Maloney, Bruce D. Cheson, Shaker R. Dakhil, Thomas P. Miller, Richard I. Fisher
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (23): 6624–6632.
https://doi.org/10.1158/1078-0432.CCR-13-1120
Published: 01 December 2013
View article titled, A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + <sup>131</sup>Iodine—Tositumomab
Open the PDF for A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + <sup>131</sup>Iodine—Tositumomab in another window
Includes: Supplementary data
Journal Articles

Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma

Steven I. Park, Jaideep Shenoi, Shani M. Frayo, Donald K. Hamlin, Yukang Lin, D. Scott Wilbur, Patrick S. Stayton, Nural Orgun, Mark Hylarides, Franz Buchegger, Aimee L. Kenoyer, Amanda Axtman, Ajay K. Gopal, Damian J. Green, John M. Pagel, Oliver W. Press
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (23): 7373–7382.
https://doi.org/10.1158/1078-0432.CCR-11-1204
Published: 30 November 2011
View article titled, Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma
Open the PDF for Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

Synergistic Effects of the Fenretinide (4-HPR) and Anti-CD20 Monoclonal Antibodies on Apoptosis Induction of Malignant Human B Cells

Daming Shan, Ajay K. Gopal, Oliver W. Press
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (8): 2490–2495.
Published: 01 August 2001
View article titled, Synergistic Effects of the Fenretinide (4-HPR) and Anti-CD20 Monoclonal Antibodies on Apoptosis Induction of Malignant Human B Cells
Open the PDF for Synergistic Effects of the Fenretinide (4-HPR) and Anti-CD20 Monoclonal Antibodies on Apoptosis Induction of Malignant Human B Cells in another window